drugset
drugset / Trial / NCT00990496

A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)

NCT00990496 ↗

Phase 1 Terminated 25 enrolled Milton S. Hershey Medical Center
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to determine the safety and efficacy of the infusion of partially matched, allogeneic, CMV specific cytotoxic T cells (CTL) for patients with GBM that have failed primary therapy.

Timeline

Start
2009-09
Primary completion
2010-10-28
Completion
2010-10-28

Outcome

Outcome not reported

Stopped (Enrollment): “Accrual goals not met”

Drugs

EvaluationDrugModalityDoseRoute
Subject CMV Specific Cytotoxic T Lymphocytes (CTL) Cell therapy 3 cells/kg —
Subject CMV Specific Cytotoxic T Lymphocytes (CTL) Cell therapy 5 cells/kg —
Background Cyclophosphamide Other / unclassified 600 mg/m2 —
Background Fludarabine Small molecule 30 mg/m2 —

Indications

glioblastoma